Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Ancient Protein-Making Enzyme Moonlights as DNA Protector

October 3, 2014 10:54 am | News | Comments

Scientists at TSRI have found that an enzyme best known for its fundamental role in building proteins has a second major function: to protect DNA during times of cellular stress. Read more...

TOPICS:

Osteoporosis Treatment May also Benefit Breast Cancer Patients

October 3, 2014 10:39 am | News | Comments

Treatment approaches to reduce the risk of metastasis associated with breast cancer may be one step closer to becoming a reality. According to a study led by a team at the Research Institute of the MUCH, findings show that medication used to treat bone deterioration in post-menopausal women may also slow skeletal metastasis caused from breast cancer. Read more...

TOPICS:

Liberia to Prosecute Man Who Brought Ebola to US

October 3, 2014 10:21 am | News | Comments

The Liberian man infected with Ebola who brought the disease to the United States will be prosecuted when he returns home for lying on his airport screening questionnaire, Liberian authorities said. Read more...

TOPICS:
Advertisement

Salix Pharma Scuttles Cosmo Technologies Merger

October 3, 2014 10:10 am | News | Comments

Salix Pharmaceuticals is scrapping its merger with the subsidiary of an Italian drugmaker after the U.S. created new limitations on the tax benefits of incorporating overseas. Read more...

TOPICS:

EU OKs Eli Lilly's $5.4B Bid for Novartis Division

October 3, 2014 10:00 am | News | Comments

The European Union's antitrust authority says it has approved the $5.4 billion sale of Novartis' animal health division to U.S. pharmaceutical firm Eli Lilly. The 28-nation bloc's executive Commission said Friday the sale won't hinder competition because the merged firm will continue to face a number of strong competitors. Read more...

TOPICS:

Intarcia Announces Positive Results for Type 2 Diabetes Therapy

October 2, 2014 3:33 pm | News | Comments

Intarcia Therapeutics announced successful top-line results from two of its four phase 3 clinical trials for ITCA 650 . The first trial, FREEDOM-1, was a placebo-controlled, double-blind phase 3 clinical trial that tested the efficacy and safety of ITCA 650 in patients with type 2 diabetes against placebo. Read more...

TOPICS:

Ariad's Lung Cancer Drug Receives FDA Breakthrough Therapy Designation

October 2, 2014 3:21 pm | News | Comments

Ariad Pharmaceuticals, Inc. announced that its investigational cancer medicine, AP26113, has received Breakthrough Therapy designation by the FDA for the treatment of patients with anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who are resistant to crizotinib. Read more...

TOPICS:

NKT Therapeutics’ Sickle Cell Disease Drug Receives FDA Fast Track

October 2, 2014 2:42 pm | News | Comments

NKT Therapeutics announced that FDA has granted Fast Track designation to NKTT120, the company’s lead therapeutic being developed for the treatment of sickle cell disease. Read more...

TOPICS:
Advertisement

Lilly Discontinues Development of Lupus Drug

October 2, 2014 2:33 pm | News | Comments

Eli Lilly and Company announced it will discontinue development of tabalumab­ -- being studied for the treatment of systemic lupus erythematosus (SLE, commonly known as lupus) -- due to insufficient efficacy in two pivotal Phase 3 trials. Read more...

TOPICS:

Experimental Ebola Vaccine Processed in Maryland

October 2, 2014 2:22 pm | News | Comments

The National Institute of Allergy and Infectious Diseases said an experimental Ebola vaccine is being processed at a facility in Frederick. The Frederick News-Post reported that the vaccine is a joint project between the federal agency and GlaxoSmithKline. Read more...

TOPICS:

Amgen Announces Positive Data for Cholesterol-Lowering Medication

October 2, 2014 2:12 pm | News | Comments

Amgen announced The Lancet published data from two Phase 3 studies, RUTHERFORD-2 and TESLA, that showed treatment with evolocumab, a novel investigational low-density lipoprotein cholesterol (LDL-C)-lowering medication, resulted in a statistically significant reduction in LDL-C compared to placebo in patients with different types of familial hypercholesterolemia (FH). Read more...

TOPICS:

Takeda Announces Phase 3 Data for UC, Crohn's Drug

October 2, 2014 10:29 am | News | Comments

Takeda announced that new data from GEMINI LTS, a Phase 3, ongoing, open-label extension study of Entyvio (vedolizumab) for the treatment of adults with moderately to severely active UC and CD will be presented as oral presentations during the 21st United European Gastroenterology Week in Vienna, Austria. Read more...

TOPICS:

Japan Starts World-First Stem Cell Trial, Plans More

October 2, 2014 10:20 am | by Cynthia Fox, Science Editor | Articles | Comments

The first patient has been treated, by Japan’s Riken Institute, in the world’s first clinical study of stem cells made from ordinary mature cells. The cells were retinal pigment epithelial (RPE) cells, but they began as a macular-degeneration patient’s skin cells.

TOPICS:

High-Cholesterol Drug Data Lifts Esperion

October 2, 2014 10:13 am | News | Comments

Shares of Esperion Therapeutics surged in aftermarket trading after the company reported positive clinical trial results for its experimental high-cholesterol drug ETC-1002. Read more...                   

TOPICS:

Discovery Helps to Spot What Makes a Good Drug

October 2, 2014 10:03 am | News | Comments

A new test developed by researchers from The University of Manchester could revolutionize the discovery of new prescription drugs. The test will help determine which drugs are unlikely to work at an early stage, speeding up the time it takes to make safe and effective medicines available. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading